25555-57-1 Usage
Description
Cannabigerolic acid (CBGA) is a non-psychoactive cannabinoid that serves as the precursor to THCA, CBDA, and CBCA cannabinoids in the Cannabis plant. It is a dihydroxybenzoic acid derivative, specifically olivetolic acid with a geranyl group substitution at the 3-position. CBGA has been reported to have potential efficacy in the treatment of cancer and schizophrenia. It is utilized in various applications, including testing methods for Cannabis potency, impurity profiling, pharmaceutical research, and forensic analysis.
Uses
Used in Pharmaceutical Research:
Cannabigerolic acid is used as a research compound for its potential therapeutic effects on cancer and schizophrenia. It is being investigated for its ability to modulate various signaling pathways and exhibit synergistic effects when combined with conventional treatments, enhancing their efficacy and sensitivity.
Used in Cannabis Potency Testing:
CBGA is used as a reference material in high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC/MS), or gas chromatography-mass spectrometry (GC/MS) methods for determining the potency of Cannabis products. This helps ensure the accurate measurement and labeling of cannabinoid content in these products.
Used in Impurity Profiling:
Cannabigerolic acid is utilized as a reference compound in the analysis of impurities and contaminants in Cannabis products. This is crucial for maintaining product quality, safety, and compliance with regulatory standards.
Used in Forensic Analysis:
CBGA is employed as a reference material in forensic analysis to identify and quantify cannabinoids in various samples, such as those related to criminal investigations or legal proceedings.
Used in Drug Development:
Cannabigerolic acid is used as a starting material for the synthesis of other cannabinoids, such as Delta9-tetrahydrocannabinol (THC), which is the principal psychoactive constituent of the Cannabis plant. This makes CBGA a valuable compound in the development of new pharmaceuticals and therapeutic agents targeting various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 25555-57-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,5,5 and 5 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 25555-57:
(7*2)+(6*5)+(5*5)+(4*5)+(3*5)+(2*5)+(1*7)=121
121 % 10 = 1
So 25555-57-1 is a valid CAS Registry Number.
InChI:InChI=1/C22H32O4/c1-5-6-7-11-17-14-19(23)18(21(24)20(17)22(25)26)13-12-16(4)10-8-9-15(2)3/h9,12,14,23-24H,5-8,10-11,13H2,1-4H3,(H,25,26)/b16-12+
25555-57-1Relevant articles and documents
CANNABINOID DERIVATIVES
-
Paragraph 0141, (2021/06/04)
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2 is methyl, R3 is CsHn, R4 is -C(O)N(R4a)(R4b), R5 is H, R6 is OH, and R7 is H. Compounds of the present disclosure were tested in agonist and antagonist mode for both the CB1 and CB2 receptors. The tested compounds were generally found to exhibit activity in antagonist mode at the CB1 and CB2 receptor.
METHODS OF SYNTHESIZING CANNABIGERGOL, CANNABIGEROLIC ACID, AND ANALOGS THEREOF
-
Paragraph 00111-00114, (2021/11/20)
Disclosed are methods for preparing carmabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising CBG or the CBG analog. The method may further comprise separating the CBG or the CBG analog for the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a CBGA analog are also disclosed. The present disclosure also provides high purity CBG, CBGA and analogs thereof. CBG can be useful as a neuroprotectant, an antibacterial agent, etc.
CANNABINOID DERIVATIVES
-
Paragraph 0159-0160, (2021/06/22)
This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.
